Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.

Peterson LB, Bell CJM, Howlett SK, Pekalski ML, Brady K, Hinton H, Sauter D, Todd JA, Umana P, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Klein C, Hosse RJ, Wicker LS.

J Autoimmun. 2018 Dec;95:1-14. doi: 10.1016/j.jaut.2018.10.017. Epub 2018 Nov 13.

2.

p95HER2-T cell bispecific antibody for breast cancer treatment.

Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escriva-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaat1445. doi: 10.1126/scitranslmed.aat1445.

3.

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.

Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, Ast O, Giusti AM, Wartha K, Runza V, Xu W, Kienast Y, Cannarile MA, Levitsky H, Romagnoli S, De Palma M, Rüttinger D, Ries CH.

J Exp Med. 2018 Mar 5;215(3):859-876. doi: 10.1084/jem.20171440. Epub 2018 Feb 7.

4.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.

Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.

5.

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, von Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umaña P.

Clin Cancer Res. 2016 Jul 1;22(13):3286-97. doi: 10.1158/1078-0432.CCR-15-1696. Epub 2016 Feb 9.

6.

Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.

Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, Yang X, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Umana P, Klein C, Hosse RJ, Wicker LS, Peterson LB.

J Autoimmun. 2015 Jan;56:66-80. doi: 10.1016/j.jaut.2014.10.002. Epub 2014 Oct 30.

7.

Characterization of virus-like particle assembly for DNA delivery using asymmetrical flow field-flow fractionation and light scattering.

Citkowicz A, Petry H, Harkins RN, Ast O, Cashion L, Goldmann C, Bringmann P, Plummer K, Larsen BR.

Anal Biochem. 2008 May 15;376(2):163-72. doi: 10.1016/j.ab.2008.02.011. Epub 2008 Feb 19.

PMID:
18342613
8.

Mx1 and IP-10: biomarkers to measure IFN-beta activity in mice following gene-based delivery.

Petry H, Cashion L, Szymanski P, Ast O, Orme A, Gross C, Bauzon M, Brooks A, Schaefer C, Gibson H, Qian H, Rubanyi GM, Harkins RN.

J Interferon Cytokine Res. 2006 Oct;26(10):699-705.

PMID:
17032164
9.

Pharmacogenomics of HIV.

Ast O, Lüke W.

Curr Opin Mol Ther. 2004 Jun;6(3):302-7. Review.

PMID:
15264433
10.

The use of virus-like particles for gene transfer.

Petry H, Goldmann C, Ast O, Lüke W.

Curr Opin Mol Ther. 2003 Oct;5(5):524-8. Review.

PMID:
14601522
11.

Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies.

Goldmann C, Petry H, Frye S, Ast O, Ebitsch S, Jentsch KD, Kaup FJ, Weber F, Trebst C, Nisslein T, Hunsmann G, Weber T, Lüke W.

J Virol. 1999 May;73(5):4465-9.

12.

A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.

Ast O, Jentsch KD, Schramm HJ, Hunsmann G, Lüke W, Petry H.

J Virol Methods. 1998 Mar;71(1):77-85.

PMID:
9628224
13.

Supplemental Content

Support Center